



January 1, 2024

Dear University of Arkansas System Member,

MedImpact Healthcare Systems, Inc., (MedImpact) on behalf of the University of Arkansas System Health Plan, is providing information regarding your prescription benefit plan that may affect you. **Please continue to read this entire letter.**

For several years extended-release ADHD medications have not been covered on the University's pharmacy formulary for health plan participants who are aged 26 and older. However, immediate-release ADHD medications are available on the formulary such as:

- **DEXTROAMPHETAMINE/AMPHETAMINE**
- **METHYLPHENIDATE HCL**

Outside of the formulary, until 1/1/2024, members aged 26 and above were able to purchase extended-release ADHD medications under the plan's now closed "tier 4" option. Tier 4 allowed members to access the MedImpact contracted pricing on medications that are not covered in the formulary versus the pharmacy provider's standard retail rate. Overall, tier 4 pricing has been phased out due to processing issues in managing out-of-pocket accumulators and the confusion it created for pharmacies and members. Extended-release ADHD medications for those age 26 and above are one of the last to be removed. Members may continue to purchase these medications but may experience a price increase when refilling prescriptions as they will not process through the pharmacy under the MedImpact discount.

Pharmacy benefits are subject to terms, conditions and eligibility as outlined in the benefit documentation in effect at the time services are provided. The above change to your prescription benefit plan has been directed by the University's Pharmacy Advisory Committee.

Sincerely,

MedImpact and the University of Arkansas Pharmacy Advisory Committee

The University of Arkansas System's' prescription drug formulary, administered by MedImpact, is maintained by the University of Arkansas System's Pharmacy Advisory Committee. The Pharmacy Advisory Committee is composed of both faculty and clinical pharmacists, who advise the Committee on the most recent medical research results. The recommendations by the committee are based on the latest available evidence-based studies.